Back to library
MetabolicSubcutaneous
HGH Fragment 176-191
Also known as: HGH Frag · Fragment 176-191
C-terminal fragment of human growth hormone identical to the AOD-9604 sequence in concept but supplied as the bare 176-191 peptide without AOD's tyrosine modification. Retains lipolytic activity at adipocyte beta-3 receptors without GH-receptor agonism.
At a glance
- Half-life
- 24 minutes
- Common route
- Subcutaneous
- Typical dose range
- 250–500mcg
- Stability (reconstituted)
- 30days refrigerated
Best timing
Fasted, AM and/or pre-cardio. Daily dosing on a 5-on-2-off cycle is common in research community protocols.
Contraindications
- Pregnancy
- Severe diabetes (theoretical insulin sensitivity effects)
- Known GH-related peptide sensitivity
Watch symptoms
- Minimal side effect profile in published animal studies
- Mild injection site reactions
- Stability is slightly worse than AOD-9604 due to lack of stabilizing modification
- Limited modern human trial data outside AOD-9604 program
Citations